Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline Review, H2 2017’, provides an overview of the Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ebolavirus Infections (Ebola Hemorrhagic Fever) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Ebolavirus Infections (Ebola Hemorrhagic Fever)

The report reviews pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics and enlists all their major and minor projects

The report assesses Ebolavirus Infections (Ebola Hemorrhagic Fever) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Ebolavirus Infections (Ebola Hemorrhagic Fever)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Ebolavirus Infections (Ebola Hemorrhagic Fever)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Ebolavirus Infections (Ebola Hemorrhagic Fever) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Adimab LLC

Akshaya Bio Inc

AnGes MG Inc

ANP Technologies Inc

Arno Therapeutics Inc

Atreca Inc

BioCryst Pharmaceuticals Inc

BioFactura Inc

Cadila Healthcare Ltd

Celgene Corp

Cocrystal Pharma Inc

Eisai Co Ltd

Emergent BioSolutions Inc

Enyo Pharma SA

Etubics Corp

Fab'entech SA

Fujifilm Holdings Corporation

Gilead Sciences Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

Hemispherx Biopharma Inc

Humabs BioMed SA

Immune Response BioPharma Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

Johnson & Johnson

Kineta Inc

Medicago Inc

Merck & Co Inc

Microbiotix Inc

Micropharm Ltd

NanoViricides Inc

Navigen Inc

Novavax Inc

Peregrine Pharmaceuticals Inc

Phelix Therapeutics LLC

PlantForm Corp

Profectus BioSciences Inc

RedHill Biopharma Ltd

Regeneron Pharmaceuticals Inc

Rodos BioTarget GmbH

SignPath Pharma Inc

Sirnaomics Inc

Soligenix Inc

Taiga Biotechnologies Inc

Tamir Biotechnology Inc

Theravectys SA

Vaccibody AS

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Overview 6

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Development 7

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Therapeutics Assessment 22

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Companies Involved in Therapeutics Development 32

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Drug Profiles 56

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Dormant Projects 233

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Discontinued Products 237

Ebolavirus Infections (Ebola Hemorrhagic Fever) - Product Development Milestones 238

Appendix 252

List of Tables

List of Tables

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Abivax SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Adimab LLC, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Akshaya Bio Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by AnGes MG Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by ANP Technologies Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Arno Therapeutics Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Atreca Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioCryst Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by BioFactura Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Cadila Healthcare Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Celgene Corp, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Cocrystal Pharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Eisai Co Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Emergent BioSolutions Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Enyo Pharma SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Etubics Corp, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fab'entech SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Fujifilm Holdings Corporation, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Gilead Sciences Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by GlaxoSmithKline Plc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Globavir Biosciences Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Hemispherx Biopharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Humabs BioMed SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Immune Response BioPharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Immunovaccine Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Integrated BioTherapeutics Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Johnson & Johnson, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Kineta Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Medicago Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Merck & Co Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Microbiotix Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Micropharm Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by NanoViricides Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Navigen Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Novavax Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Peregrine Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Phelix Therapeutics LLC, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by PlantForm Corp, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Profectus BioSciences Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by RedHill Biopharma Ltd, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Regeneron Pharmaceuticals Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Rodos BioTarget GmbH, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by SignPath Pharma Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Sirnaomics Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Soligenix Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Taiga Biotechnologies Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Tamir Biotechnology Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Theravectys SA, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by Vaccibody AS, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Pipeline by XBiotech Inc, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Ebolavirus Infections (Ebola Hemorrhagic Fever) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Ebolavirus Infections (Ebola Hemorrhagic Fever), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports